Clinical trials: Heart Failure, Unspecified
ADHF
Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions
The purpose of this study is to investigate the utility of Venus 1000 in predicting 30-day hospital readmissions for acute decompensated heart failure.
- Trial name
- NCT02003040
- Testing
- Mespere Venus 1000 CVP System
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Mespere Lifesciences Inc.
Chronic Heart Failure With Reduced Ejection Fraction
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
This is an observational study in which the health data of people with chronic heart failure with reduced ejection fraction (HFrEF) are collected using administrative claims data.
- Trial name
- NCT05974189
- Where
- Germany
- Volunteers
- 1,391 people
- Sponsor
- Bayer
Congestive Heart Failure, Cardiac Transplantation
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide).
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Trial name
- NCT00338455
- Testing
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Scios, Inc.
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORELLO (NCT07192952)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 132 sites in United States, Argentina and 21 more
- Volunteers
- 117 people
- Sponsor
- Bayer
Heart Failure, Atrial Fibrillation
Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy
The purpose of this study is to evaluate whether adding AF Suppression™ to cardiac resynchronization therapy (CRT) improves the prognosis of heart failure patients benefiting from cardiac resynchronization therapy.
- Conditions
- Heart Failure, Atrial Fibrillation, Ventricular Dysfunction
- Trial name
- MASCOT (NCT00187252)
- Testing
- Atrial Overdrive Pacing
- Where
- Italy
- Volunteers
- 380 people
- Sponsor
- Abbott Medical Devices
Heart Failure With Preserved Ejection Fraction
Surgical Resection of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction
We believe that blocking of the Greater Splanchnic Nerve (GSN) will stop Sympathetic Nervous System (SNS) activity from reaching the splanchnic vessels and result in a redistribution of blood volume back into the splanchnic…
- Trial name
- NCT03715543
- Testing
- Surgical Resection of the Greater Splanchnic Nerve
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 8 people
- Sponsor
- Noblewell
Heart Failure
Implementation of a Protocol Utilizing Adaptive CRT in a Normal AV Conduction, CRT Non-Response Population at Generator Replacement
IMPROVE RESPONSE is a physician initiated research study. It is a prospective, non-randomized, multi-center, post-market, U.S. Cardiac Resynchronization Therapy (CRT) in heart failure (HF) observational study.
- Trial name
- NCT03305393
- Testing
- Adaptiv CRT
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stern Cardiovascular Foundation, Inc.
Mitral Valve Insufficiency, Mitral Valve Disease
The Conveyor Study
To demonstrate that the Conveyor System can safely provide left ventricular access to deliver the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients who have been diagnosed with prior mitral…
- Conditions
- Mitral Valve Insufficiency, Mitral Valve Disease, Mitral Valve Regurgitation, Heart Failure
- Trial name
- NCT03893578
- Testing
- Mitral valve-in-valve
- Volunteers
- 10 people
- Sponsor
- Synecor, LLC
Chronic Heart Failure
Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients…
- Trial name
- NCT01439789
- Testing
- rhNRG-1
- Where
- 21 sites in China
- Volunteers
- 146 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Advanced Heart Failure
CorWave LVAS FIH Study
The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.
- Trial name
- NCT06907017
- Testing
- LVAS
- Where
- 3 sites in Australia, Kazakhstan
- Volunteers
- 20 people
- Sponsor
- CorWave
Non-Ischemic Congestive Heart Failure
Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements…
- Trial name
- NCT01502501
- Testing
- Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)
- Where
- Mexico
- Sponsor
- Ageless Regenerative Institute
Heart Failure
A Study of Ponsegromab in People With Heart Failure
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find…
- Trial name
- GARDEN TIMI 74 (NCT05492500)
- Testing
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose
- Where
- 122 sites in United States, Australia and 9 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Heart Failure, Arrhythmia
The HF-HRV Registry
The Registry will evaluate how HRV Monitor diagnostics change after cardiac resynchronization therapy in patients with heart failure.
- Trial name
- NCT00236236
- Testing
- Cardiac Resynchronization Therapy
- Volunteers
- 1,400 people
- Sponsor
- Boston Scientific Corporation
Heart Failure，Congestive
Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to…
- Trial name
- NCT03519477
- Testing
- Sano Patient Medication Profile
- Where
- United States
- Sponsor
- Precera Bioscience, Inc.
Heart Failure
Attain StarFix™ Model 4195 Left Ventricular Lead
People who have abnormal heart beats, or whose heart does not beat on its own, may need an electronic device called a pacemaker or a defibrillator.
- Trial name
- NCT00269230
- Testing
- Pacing Lead
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 441 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the…
- Trial name
- CLEOPATTRA (NCT07207811)
- Testing
- NNC6019-0001
- Where
- 299 sites in United States, Argentina and 18 more
- Volunteers
- 1,280 people
- Sponsor
- Novo Nordisk A/S
Diabetic Cardiomyopathies
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
- Trial name
- NCT04083339
- Testing
- AT-001
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 675 people
- Sponsor
- Applied Therapeutics, Inc.
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
- Trial name
- AMBER-HFpEF (NCT06793371)
- Testing
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- Where
- 26 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cytokinetics
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Heart Failure, Asthma
Economic Evaluation of Heart Failure Management in Colombian Clinics
Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.
- Trial name
- EconoHeart (NCT01084564)
- Volunteers
- 300 people
- Sponsor
- AstraZeneca